Catalyst
Slingshot members are tracking this event:
Idera (IDRA) Agrees to Global License Agreement with Vivelix Pharma to Develop IMO-9200 for Non-Malignant Gastrointestinal (GI) Disorders
Do you think this event is important to the companies below? How will it affect their stock price?
| Related Companies | Importance
|
Impact on Stocks
|
||||
|---|---|---|---|---|---|---|
| IDRA |
|
|
Vivelix Pharmaceuticacls |
|
|
|
Slingshot Insights Explained
Catalyst Date
Occurred on:
Nov 28, 2016
Related Projects
-
Don’t see a project related to the catalyst you care about?
Related Keywords
Global License Agreement, Imo-9200, Non-malignant Gastrointestinal, Disorders
